Skip to content

Study · Observational study · n = 206 · 2025

2 results

Sleeve Gastrectomy Versus Semaglutide for Weight Loss in a Severely Obese Minority Cohort: A Propensity-Matched Study.

Masrur MA, Manueli Laos EG, Zhang L, Acosta A, Pirzada A, Schlottmann F

Obesity surgery29 Jan 2025Cited by 6 (Europe PMC)

PMID39875789 (opens in a new tab)DOI10.1007/s11695-025-07712-z (opens in a new tab)PepBankPUB-39875789
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In severely obese minority patients, semaglutide gave less total weight loss at 12 months than sleeve gastrectomy (2% versus 32%).

    In plain wordsIn severely obese patients, semaglutide gave much less weight loss at 12 months than sleeve gastrectomy surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal weight loss at 12 months
    Study

    n = 206

    Comparator
    Sleeve gastrectomy
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Total weight loss
    2%
    semaglutide, 12 months
    Total weight loss
    32%
    sleeve gastrectomy, 12 months

    Source sentences

    Summary
    The SG group consistently outperformed semaglutide regarding weight loss at all follow-up periods, with the largest difference observed at 12-month post-intervention (total weight loss 32% vs. 2%, p < 0.001).
    1 context sentence
    Summary · context
    The first cohort consisted of patients prescribed semaglutide from January to December 2022, and the second one included patients who underwent SG during the same period.
  2. 02HumanObservational studyEfficacy outcome

    In severely obese minority patients, semaglutide gave less weight loss than sleeve gastrectomy at every follow-up, including 3 and 6 months.

    In plain wordsIn severely obese patients, semaglutide gave less weight loss than sleeve gastrectomy surgery at every check, including 3 and 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss at 3 and 6 months
    Study

    n = 206

    Comparator
    Sleeve gastrectomy
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 3, 6 and 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The SG group consistently outperformed semaglutide regarding weight loss at all follow-up periods
    1 context sentence
    Summary · context
    The first cohort consisted of patients prescribed semaglutide from January to December 2022, and the second one included patients who underwent SG during the same period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.